论文部分内容阅读
目的:探讨短期胰岛素泵强化(CSII)和胰岛素多点皮下注射(MDI)强化治疗初诊2型糖尿病患者胰岛β细胞功能改变。方法:38例空腹血糖>7.0mmol/1的初诊2型糖尿病惠者随机分为CSII组和MDI组,CSII组共24人,MDI组其14人,进行一个月强化治疗,以未梢空腹血糖<6.1mmol/l和餐后2血糖<78mmol/l为血糖控制目标。根据血糖调整胰岛素用量,比较两组治疗前后的口服葡萄糖耐量试验胰岛素和C肽曲线下面积、Homa胰岛功能(Homaβ)和抵抗指数(HOMARI)。结果:在治疗前后,两组间的胰岛素和C肽曲线下面积、HOMA胰岛功能(Homaβ)和抵抗指数(Homaresistantinsulin,HomaRI),无明显的统计学意义。除HOMARI外,组内其他上述指标在治疗前后有明显的统计学差别。
Objective: To investigate the changes of pancreatic β-cell function in newly diagnosed type 2 diabetic patients treated with short-term insulin pump boost (CSII) and insulin multi-subcutaneous injection (MDI). Methods: Thirty-eight patients with newly diagnosed type 2 diabetes with fasting blood glucose> 7.0mmol / 1 were randomly divided into CSII group and MDI group. There were 24 patients in CSII group and 14 in MDI group. One month intensive treatment was performed with no fasting blood glucose <6.1mmol / l and postprandial 2 glucose <78mmol / l for the purpose of glycemic control. According to the blood sugar, the amount of insulin was adjusted. The area under the curve of insulin and C-peptide, Homa β and resistance index (HOMARI) of oral glucose tolerance test before and after treatment were compared between the two groups. Results: Before and after treatment, the area under the curve of insulin and C-peptide, HOMA and HomaRI between the two groups had no statistical significance. With the exception of HOMARI, there was a statistically significant difference between the other indexes in the group before and after treatment.